Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer.

doi:10.1158/2767-9764.CRC-24-0294

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer.

Cancer research communications - 1 Dec 2024

Kjeldsen Maj K, Jørgensen Morten, Grønseth Dina Sofie B, Schønemann-Lund Martin, Nyvang Gitte-Bettina, Haslund Charlotte Aaquist, Knudsen Anja Oer, Motavaf Anne Krejbjerg, Malander Susanne, Anttila Maarit, Lindahl Gabriel, Mäenpää Johanna, Dimoula Maria, Werner Theresa L, Iversen Trine Zeeberg, Hietanen Sakari, Fokdal Lars, Dahlstrand Hanna, Bjørge Line, Birrer Michael J, Mirza Mansoor R, Rossing Maria

Abstract excerpt

ABSTRACT: The management of advanced epithelial ovarian cancer (AOC) has undergone significant advancements with the emergence of molecular diagnostics, particularly in predicting responses to PARP inhibitors (PARPi) based on homologous recombination deficiency (HRD) status. However, understanding sensitivity and resistance beyond HRD status remains elusive. This study aims to explore molecular factors that may...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Drug Resistance, Neoplasm

Share to Mutation

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 39591206
DOI: 10.1158/2767-9764.CRC-24-0294
PMCID: PMC11670052

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer.PMID 39591206Read ↗

HRDetect in Ovarian Carcinoma: Stratification and Therapeutic ImplicationsSemantic proximity Read ↗

Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trialSemantic proximity Read ↗

Unraveling Homologous Recombination Deficiency in Ovarian Cancer: A Review of Currently Available Testing PlatformsSemantic proximity Read ↗

Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnosticsSemantic proximity Read ↗

Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD?Semantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis and TreatmentSemantic proximity Read ↗

How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literatureSemantic proximity Read ↗

Homologous recombination deficiency-driven genomic instability in ovarian cancer as an indicator of BRCA1 and BRCA2 variant pathogenicity.Semantic proximity Read ↗

Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors.Semantic proximity Read ↗

Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian CancerSemantic proximity Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical PerspectivesSemantic proximity Read ↗

Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.